Purpose: To evaluate the activity and toxicity of gemcitabine and carboplatin in consecutive patients presenting with locally advanced or metastatic transitional cell carcinoma of the urothelium (TCC).
Introduction
Transitional cell carcinoma (TCC) of the urothelium mostly occurs in elderly men and women. The median age of patients presenting with TCC of the bladder in Australia in 1996 was 70 years [1] . Often these patients have poor renal function and poor performance status [2] . For much of the last fifteen years the standard chemotherapy for this disease has been a combination of methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) which has an overall response rate of 40%-72% and a median survival of 13 months and is superior to cisplatin alone or other cisplatin-based combinations [3] [4] [5] . MVAC is toxic with a treatment-related death rate of up to 3% and a neutropenic sepsis rate of 25% and is difficult to give to patients who are elderly, and those who have impaired performance status or renal function [3] .
Llado et al. recently predicted that approximately half of all patients presenting with TCC of the urothelium would be ineligible for cisplatin-based regimens based on their poor performance status and impaired creatinine clearance [2] . Carboplatin has several advantages over cisplatin in the palliative setting. Its more favourable toxicity profile and the ability to attain more predictable haematological toxicity by dosing to AUC make it a good alternative in patients with imperfect renal function. Single agent carboplatin has response rates ranging from 8%-18% in TCC of the urothelium [6] [7] [8] . However, attempts have failed to make cisplatin combination treatment less toxic but with similar activity by replacing cisplatin with carboplatin in the combination [9, 10] .
Gemcitabine, a new nucleoside analogue, has shown promising activity in TCC of the urothelium. Single agent response rates of 23%-28% have been reported even in previously treated patients [11] [12] [13] [14] . Gemcitabine is well tolerated and therefore an ideal candidate for combination with other active agents. A recently published phase 111 trial comparing gemcitabine and cisplatin with MVAC showed no significant differences in overall survival or response rates [15] . The cisplatin and gemcitabine arm had significantly better safety profile and tolerability prompting a call for this combination to become the standard of care for these patients. However, the presence of cisplatin in this combination still makes a significant proportion of patients with TCC ineligible for this treatment.
The current study was designed to examine the efficacy and toxicity of carboplatin and gemcitabine in patients with metastatic TCC of the urothelium. Since carboplatin can be dosed using GFR and gemcitabine is not renally excreted, this combination is attractive in patients with urothelial cancer who often have impaired renal function. The combination of carboplatin and gemcitabine has been evaluated in the setting of nonsmall-cell lung cancer (NSCLC) and has demonstrated manageable toxicity [16, 17] . Data from phase II trials in NSCLC show that a 21-day schedule with gemcitabine on day one and eight is less toxic than a 28-day schedule with gemcitabine on day 1, 8 and 15 with no apparent compromise of efficacy and this schedule was selected for this study [18. 19] .
priate. All patients who received at least one dose were assessable for toxicity and those receiving at least two cycles were assessable for response. Overall survival was measured from the date of study entry until death and time to progression was measured from the date of study entry until progression or death.
Standard WHO criteria were used to assess response. Response criteria were as follows: 1) complete response was defined as the disappearance of all known disease; 2) partial response was defined as a decrease of 50% or greater in the total cross-sectional area of measurable lesions, and 3) progressive disease was defined as a 25% or greater increase in the overall sum of measurable lesions compared with baseline. Patients who achieved a response were re-scanned after a further three cycles of chemotherapy to confirm their response. Criteria for stopping treatment included tumour progression, serious toxicity or patient request. Following completion of treatment patients were assessed every three months until disease progression or death.
Patients and methods

Patients
This was a pilot study of patients had locally advanced or metastatic transitional cell carcinoma of the bladder, ureter or renal pelvis. Wide entry criteria were adopted in seventeen sequential patients referred for treatment. Patients were required to have histologically or cytologically proven TCC and measurable disease. Prior cytotoxic treatment either in the adjuvant setting or for metastatic disease was permitted if the treatment had been completed at least six months prior to enrollment in the study. Prior radiotherapy was permitted but must have been completed at least six weeks prior to enrollment. Patients were required to have a performance status (Eastern Cooperative Oncology Group) of three or less and have adequate bone marrow reserve (WBC count > 3.5 x IO 9 /1, platelets > 100 x 10 9 /l, and haemoglobin > lOg/dl). There were no restrictions with regard to hepatic function or creatinine clearance. Exclusion criteria included known CNS metastases, pregnancy and prior malignancy (except in situ carcinoma of the cervix or treated basal cell carcinoma of the skin) within five years.
Treatment schedule
Patients were treated on an outpatient basis. Gemcitabine 1.000 mg/m 2 was given by intravenous infusion over 30 minutes on day I and 8 of a 21-day cycle. Carboplatin dosed to an AUC of 5 was given as an intravenous infusion over one hour on day I of a 21-day cycle. Creatinine clearance was determined by using serum creatinine and the Cockcroft and Gault formula [20] , Day eight Gemcitabine was omitted if the neutrophil count was <1.0x 10 9 /l or platelet count < 100 x 10 9 /l Carboplatin dose was adjusted for renal function with each cycle. The dose of both drugs was reduced 10%-20% if the patient had developed grade 3 or 4 neutropema or thrombocytopenia in the previous cycle. Patients were reviewed every three weeks for toxicity. All toxicity was recorded according to WHO criteria A complete blood count and differential were performed on day 1 and 8 of all cycles and on day 14 of the first cycle. Dose of gemcitabine was increased by 10% to 20% if the nadir neutrophil count was > 1.5 x IO 9 /1. Cycles were delayed one week if the absolute neutrophil count was <l.5 x 10 9 /l or platelets < 100 x IO 9 /1.
Blood transfusions, anti-emetics and analgesics were administered as appropriate Patients received a maximum of six cycles unless they developed progressive disease or toxicity unacceptable to the patient
Outcome evaluation
Patients were evaluated for response after every three cycles with physical examination, computed tomography or chest X-ray as appro-
Results
Patient characteristics
From June 1998 to October 1999, all patients seen at Westmead Hospital with advanced TCC were treated on this protocol. Seventeen patients were treated and all are assessable for toxicity and response. One patient had a resection of residual disease following a partial response and was not included in the survival analysis. This analysis was completed in July 2000. Table 1 provides a summary of patient's baseline characteristics. Patient age ranged from 54-78 years with a median age of 69 years.
The majority (76.5%) of patients had the bladder as the primary site of disease. Nine patients (52.9%) had visceral sites of metastases (liver or lung) and eleven patients (64.7%) had multiple sites of metastatic disease. Two patients had locally advanced tumour in the bladder as their only site of disease (both T4b). Three patients had previously received adjuvant or neoadjuvant chemotherapy and one patient had previously received chemotherapy for metastatic disease. Three patients had previously received radiotherapy to the pelvis.
The study group included patients with relatively poor renal function. Calculated creatinine clearance ranged from 34 ml/min to 90 ml/min with a median creatinine clearance of 56.4 ml/min. Fourteen of seventeen patients had a creatinine clearance of < 60 ml/min.
Study treatment
Patients received a median number of five cycles of chemotherapy (range 2-6). Of the seventeen patients entered on the study seven patients completed six cycles of treatment. Six patients stopped treatment due to disease progression, two patients stopped due to toxicity and two patients were deemed to have had adequate treatment after five cycles.
The day 8 dose of gemcitabine was omitted on 13 out of a total of 80 cycles due to neutropenia or thrombocytopenia. Two patients had cycle delays due to prolonged neutropenia or thrombocytopenia. Dose reductions were required in seven patients due to grade 3 or 4 neutropenia or thrombocytopenia in the previous cycle. Fifteen patients (88.2%) received at least 85% of the planned dose of carboplatin and eleven patients (65%) received at least 85% of the planned dose of gemcitabine. One patient had a dose increase due to an inadequate nadir neutrophil count.
Tumour response
In the 17 patients assessable for response there were 3 (17.6%) complete responses and 7 (41.2%) partial responses for an overall response rate of 10 of 17 or 58.8%. In addition three patients (17.6%) had stable disease and four patients (23.5%) had progressive disease. Two patients who had previously had adjuvant chemotherapy had partial responses and the one patient who had previously had MVAC for metastatic disease had a partial response. Two of the three patients who had previously had pelvic radiotherapy had a partial response and one of these was confined to within the radiation field. Among the nine patients with visceral disease there were four partial responses, one stable disease and four patients with progressive disease. months) (Figure 2 ). One patient was excluded from the calculation of time to progression and overall survival because she had resection of residual disease in the bladder following a partial response to chemotherapy. She remains alive and free of disease.
Adverse events
The major toxicity encountered with this regimen was haematological. Table 2 contains a list of the worst toxicity encountered for each patient. Twelve (70%) of seventeen patients had grade 3 or 4 granulocytopenia and eight (47%) of 17 patients had grade 3 or 4 thrombocytopenia. There were no admissions for neutropenic sepsis and no treatment related deaths. One patient had minor epistaxis but was concurrently anticoagulated for deep venous thrombosis. Four patients required platelet transfusions and eight patients required red blood cell transfusions. Only 1 patient was admitted as the result of toxicity with prolonged emesis. There was no renal toxicity. One patient had moderate mucositis and two patients had grade 3 emesis. Study treatment was discontinued in two patients because of toxicity.
Discussion
This phase 11 study demonstrates that carboplatin and gemcitabine have significant activity against advanced TCC of the urothelium with manageable toxicity in a group of patients with relatively poor prognostic factors and that are typical for this disease. Patients on this study were elderly (median age 69 years), had relatively poor renal function (median creatinine clearance 56 ml/min), and a significant proportion had visceral metastases (53%) and poor performance status (30% ECOG 2). All patients referred to Westmead Hospital with advanced urothelial TCC during the period of the study were treated on this protocol. No patient was excluded because of age or other prognostic feature and so this study group accurately reflects patients seen in clinical practice. Despite these relatively poor clinical characteristics the treatment was well tolerated. Although a significant proportion of patients had some haematological toxicity there were few clinical sequelae. Only one patient was admitted as a result of toxicity, attesting to the practicality of using this schedule in the outpatient setting. There were no cases of neutropenic sepsis. The median number of cycles given was 5 and all 17 patients had at least two cycles of treatments. These data indicate that the doses selected for this combination were suitable for this group of patients. This data is distinct from published series of the 'gold standard' MVAC where patients are younger and have a better performance status than an unselected TCC population. The median age of patients in phase II and III studies of MVAC is 56 to 63 years and patients with moderately poor performance status were excluded from these studies [3] [4] [5] 15] . Table 3 compares selected prognostic and outcome data from the current study and the major studies of MVAC and gemcitabine/cisplatin [3, 4, 15, 21] . Although the median survival is lower in the current study, age and performance status, two major prognostic factors, are also worse.
These results using carboplatin and gemcitabine are also similar to published phase II response rates using other combination of the newer agents such as carboplatin/paclitaxel (20.7%-52%) or gemcitabine/paclitaxel (53%-60%) [22] [23] [24] [25] [26] . This pilot study clearly shows significant activity and an acceptable toxicity profile of this combination in an unselected group of patients with this disease. Of considerable importance is that all patients had a sufficient cumulative dose to adequately test the chemosensitivity of their tumour, which would be difficult to achieve using a more toxic regimen. This combination warrants further study as it can be applied to patients with poor performance status and those with imperfect renal function. Given the relatively short overall survival and time-to-disease progression from this regimen, it may not be suitable for patients with good performance status and renal function who may withstand more aggressive treatment. A larger randomized phase II study of carboplatin and gemcitabine or docetaxel and gemcitabine is underway at this institution.
